Nuvalent's zidesamtinib NDA filing accepted by US FDA

Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial

Frost & Sullivan honours WuXi AppTec

Hemispherian secures US patent allowance expanding GLIX1 patent protection

Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA

AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination

European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis

Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer

Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer

Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin

Pulmonary Fibrosis Foundation Launches New Five-Year Strategy: The PFF is ME

Privo Technologies reports positive results from non-invasive oral cancer and high-grade dysplasia trial

Vanda Pharmaceuticals reports positive topline results from tradipitant trial in GLP-1 induced nausea and vomiting

Acumen Pharmaceuticals begins open-label extension of Phase 2 Alzheimer's study

Incyte receives positive CHMP opinion for Minjuvi in relapsed or refractory follicular lymphoma